GLP-1s reduce heart failure death, hospitalization: 3 things to know
Both semaglutide and tirzepatide were shown to “significantly reduce” the risk of hospitalization and all-cause mortality for heart failure patients, according to a study published Aug. 31 in JAMA. Researchers from Somerville, Mass.-based Mass General Brigham analyzed U.S. insurance claim data to emulate two previous semaglutide and tirzepatide trials at a larger scale, an Aug. […]
GLP-1 Receptor Agonists Linked to Reduced Risk for Developing Uveitis
TUESDAY, Sept. 2, 2025 — Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduction in the risk for developing uveitis, according to a study published online Aug. 28 in JAMA Ophthalmology.Nitesh Mohan, from the Cole Eye…
GLP-1 Drugs May Cut Dementia and Stroke Risk for Some Patients
For patients with type 2 diabetes (T2D) and obesity, glucagon-like peptide-1 (GLP-1) drugs may offer neuroprotective and cerebrovascular benefits in addition to glycemic control, a recent study found.
I Am Taking a GLP-1 Weight-Loss Medication—What Should I Know?
This JAMA Internal Medicine Patient Page describes how glucagon-like peptide-1 (GLP-1) receptor agonists work and what behaviors to adopt while using them.
A GLP-1 Pill Is Coming to Shake Up the Weight Loss Drug Market
Eli Lilly is on track to release orforglipron next year, which has showed an average of 12 percent weight loss.
Reassessment of antibody-based detection of the murine T cell GLP-1 receptor
Glucagon-like peptide 1 receptor (GLP-1R) agonists exhibit anti-inflammatory actions, yet the importance of direct immune cell GLP-1R signaling remains uncertain. Although T cells respond to GLP-1, low receptor abundance and suboptimal antisera complicate efforts to characterize immune cell GLP-1R signaling. Here, we evaluate three frequently utilized GLP-1R antibodies, revealing that several antibodies, particularly AGR-021, lack […]
Eli Lilly’s New Drugs Beyond Mounjaro and Zepbound Boost Sales
Eli Lilly and Company LLY has gained tremendous market value in the past 2-3 years due to the success of its popular GLP-1 drugs, Mounjaro for type II diabetes and Zepbound for obesity. However, Lilly has gained approvals for other new drugs within the same time frame. These include Omvoh for treating ulcerative colitis and […]
Unique and conserved endoplasmic reticulum stress responses in neuroendocrine cells
Endocrine cells are dedicated to the production and processing of hormones, from peptides to small molecules, to regulate key physiological processes, including glucose homeostasis and metabolism. Because of this relatively high productivity, endocrine cells must handle a variety of stresses from oxidative stress to the unfolded protein response of the endoplasmic reticulum (UPRER). While much […]
Novo’s Wegovy Cuts Cardio Risk by 57% Versus Tirzepatide
Novo Nordisk’s Wegovy has been on a winning streak as of late, with a metabolic dysfunction-associated steatohepatitis approval last month and prime position in the oral obesity race.
Could GLP-1 weight-loss medications like Ozempic become the ‘everything drug’?
GLP-1 agonists — including semaglutides like Ozempic and Wegovy and tirzepatides like Mounjaro and Zepbound — were originally intended to treat type 2 diabetes and obesity. But in recent months, studies have shown that these popular medications can have numerous other health benefits. Some have even claimed that GLP-1s could eventually become the new “everything […]